J-TEC
Pioneering regenerative medicine with cultured human tissues for enhanced patient care and safety.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
| JPY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (2 %) | (7 %) | (3 %) | 24 % | (2 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (5 %) | (15 %) | (18 %) | (29 %) | 11 % | (3 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (12 %) | (21 %) | (24 %) | (36 %) | 6 % | (10 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 15 % | 21 % | 27 % | 28 % | 16 % | 21 % |
Source: Company filings or news article
Related Content
Japan Tissue Engineering Co., Ltd. (J-TEC) specializes in regenerative medicine, focusing on the development and commercialization of cultured human tissues. The company serves medical professionals, patients, and regenerative medicine developers, operating primarily in the healthcare and biotechnology markets. J-TEC's business model revolves around creating and supplying high-quality, safe, and effective cultured tissues that can be used in various medical treatments and procedures. Revenue is generated through the sale of these cultured tissues and related products to hospitals, clinics, and research institutions. The company emphasizes product safety and quality assurance, ensuring that all products meet stringent regulatory standards. J-TEC also engages in continuous research and development to innovate and expand its product offerings.
Keywords: regenerative medicine, cultured tissues, biotechnology, healthcare, patient care, medical treatments, safety, quality assurance, research, innovation.
